{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:35:35Z","timestamp":1776990935014,"version":"3.51.4"},"reference-count":8,"publisher":"BMJ","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.n2602","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T15:00:10Z","timestamp":1635174010000},"page":"n2602","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home"],"prefix":"10.1136","author":[{"given":"Elisabeth","family":"Mahase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"2023030804502670000_375.oct25_8.n2602.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1077"},{"key":"2023030804502670000_375.oct25_8.n2602.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2422"},{"key":"2023030804502670000_375.oct25_8.n2602.3","unstructured":"A study of PF-07321332\/ritonavir in non-hospitalized low-risk adult participants with covid-19. ClinicalTrials.gov. Sep 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05011513."},{"key":"2023030804502670000_375.oct25_8.n2602.4","unstructured":"A study of PF-07321332\/ritonavir in nonhospitalized high risk adult participants with covid-19. ClinicalTrials.gov. Oct 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04960202."},{"key":"2023030804502670000_375.oct25_8.n2602.5","unstructured":"A post-exposure prophylaxis study of PF-07321332\/ritonavir in adult household contacts of an individual with symptomatic covid-19. ClinicalTrials.gov. Oct 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05047601."},{"key":"2023030804502670000_375.oct25_8.n2602.6","unstructured":"Pfizer starts global phase 2\/3 EPIC-PEP study of novel covid-19 oral antiviral candidate for post-exposure prophylaxis in adults. Pfizer. Sep 2021. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19."},{"key":"2023030804502670000_375.oct25_8.n2602.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2650"},{"key":"2023030804502670000_375.oct25_8.n2602.8","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008965.pub3","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"1","author":"Jefferson","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.n2602","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.n2602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T12:50:41Z","timestamp":1678279841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.n2602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":8,"alternative-id":["10.1136\/bmj.n2602"],"URL":"https:\/\/doi.org\/10.1136\/bmj.n2602","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}